

<b>Name of the Issue: Niva Bupa Health Insurance Company Limited</b>				
<b>1</b>	<b>Type of Issue</b>	Initial Public Offer		
<b>2</b>	<b>Issue Size (Rs. Mn)</b>	22,000.00*		
<i>*Source: Prospectus dated November 12, 2024</i>				
<b>3</b>	<b>Grade of issue along with name of the rating agency</b>			
	<b>Name</b>	NA		
	<b>Grade</b>	NA		
<b>4</b>	<b>Subscription Level (Number of times)</b>	1.90*		
<i>*excluding Anchor Investor Portion and after technical rejections</i>				
<i>Source: Minutes for basis of allotment dated November 12, 2024</i>				
<b>5</b>	<b>QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges</b>			
	<b>Particulars</b>	<b>%</b>		
	(i) On Allotment **	18.20		
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2024)	18.68		
	(iii) at the end of 1st FY (March 31, 2025)	18.60		
	(iv) at the end of 2nd FY (March 31, 2026)	27.09		
	(v) at the end of 3rd FY (March 31, 2027) *	Not Available		
<i>**Source: Institutions (domestic + foreign) holding as disclosed in the stock exchange filing</i>				
<i>* QIB Holding not disclosed as reporting for relevant period has not been completed.</i>				
<b>6</b>	<b>Financials of the issuer</b>			
	<b>Parameters</b>	<b>1st FY (March 31, 2025)</b>	<b>2nd FY (March 31, 2026)</b>	<b>3rd FY (March 31, 2027)*</b>
	Total Income	53,242.60	64,723	Not Available
	Net Profit/(Loss) for the period	2,135.20	1,308	Not Available
	Paid-up equity share capital	18,720.30	18,475	Not Available
	Reserves excluding revaluation reserves	40,262.20	13,715	Not Available
<i>* Financials not available as reporting for the relevant years has not been completed.</i>				
<b>7</b>	<b>Trading Status</b>			
The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")				
The equity shares have not been suspended or delisted.				
	<b>Particulars</b>	<b>Status</b>		
	(i) at the end of 1st FY (March 31, 2025)	Frequently		
	(ii) at the end of 2nd FY (March 31, 2026)	Frequently		
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available		
<i>* Trading status not disclosed as the relevant fiscal years have not been completed.</i>				
<b>8</b>	<b>Change in Directors of Issuer from the disclosures in the offer document</b>			
	<b>Particulars</b>	<b>Name of Director</b>	<b>Appointed / Resigned</b>	
	(i) at the end of 1st FY (March 31, 2025)	Pradeep Pant Divya Sehgal Mohit Gupta	Cessation Resignation Appointent	
	(ii) at the end of 2nd FY (March 31, 2026)	Milind Gajanan Barve Vivek Anant Karve Chandrashekhar Bhaskar Bhav Roger William John Davis Sridhar Srinivasan Ankur Kharbanda Vishwanath Mahendra Partha Banerjee Maninder Singh Juneja Sridhar Srinivasan	Appointment Appointment Resigend Appointment Appointment Appointment Resigned Resigned Resigned	
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available	
<i>* Changes in Directors of Issuer not updated as the relevant financial years have not been completed</i>				

<b>9 Status of implementation of project/ commencement of commercial production</b>							
(i) as disclosed in the offer document		Not applicable					
(ii) Actual implementation		Not applicable					
(iii) Reasons for delay in implementation, if any		Not applicable					
<b>10 Status of utilization of issue proceeds</b>							
(i) as disclosed in the offer document							
<b>Particulars</b>		<b>Amount proposed to be financed from Net Proceeds</b>					
To meet future capital requirements towards onward lending		8000.00					
<b>Total Proceeds</b>		<b>8000.00</b>					
(ii) Actual implementation							
<b>Particulars</b>		<b>Amount proposed to be financed from Net Proceeds</b>	<b>Actual Utilisation of Net Proceeds</b>	<b>Unutilised Net Proceeds</b>			
To meet future capital requirements towards onward lending		8000.00	8000.00	0.00			
<b>Total Proceeds</b>		<b>8000.00</b>	<b>8000.00</b>	<b>0.00</b>			
<i>Source: Quarterly Results</i>							
(iii) Reasons for delay in implementation, if any		Not applicable					
<b>11 Comments of monitoring agency, if applicable</b>							
(i) Comments on use of funds		Not Applicable					
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document		Not Applicable					
(iii) Any other reservations expressed by the monitoring agency about the end use of funds		Not Applicable					
<b>12 Pricing Data</b>							
Designated Stock Exchange		NSE					
Issue Price (Rs.)		74.00					
Listing Date		14-Nov-24					
<b>Price parameters</b>		<b>At close of listing day</b>	<b>Close of 30th calendar day from listing day</b>	<b>Close of 90th calendar day from listing day</b>	<b>As at the end of the 1st FY after the listing of the issue (31st March,2025)</b>		
					<b>Closing price</b>	<b>High</b>	<b>Low</b>
Market Price		74.00	83.60	79.3	75.92	77.79	75.62
Nifty 50*		23,523.70	24,768.30	23,045.25	23,165.70	23,565.15	23,136.40
<b>Price parameters</b>		<b>As at the end of the 2nd FY after the listing of the issue (31st March,2026)</b>			<b>As at the end of the 3rd FY after the listing of the issue (31st March,2027)<sup>(1)</sup></b>		
		<b>Closing price</b>	<b>High</b>	<b>Low</b>	<b>Closing price</b>	<b>High</b>	<b>Low</b>
Market Price		70.2	95.2	67.5	Not Available	Not Available	Not Available
Nifty 50*		22,331.4	26,328.6	22,161.6	Not Available	Not Available	Not Available

\* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

**13 Basis for Issue Price**

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2025)	At the end of 1st FY (March 31,2026)	At the end of 1st FY (March 31,2027)**
<b>EPS (Diluted)</b>	<b>Company</b>				
	<i>Consolidated</i>		0.51	1.20	0.71
	<b>Peer Group:</b>				
	Star Health and Allied Insurance Company		14.48	10.99	9.47
	ICICI Lombard General Insurance Company Ltd		39.03	50.25	55.24
	The New India Assurance Company Ltd		6.77	6.29	6.29
	<b>Industry Avg</b>		<b>20.09</b>	22.51	23.67
<b>P/E</b>	<b>Company</b>				
	<i>Consolidated</i>		148.00	63.27	98.89
	<b>Peer Group:</b>				
	Star Health and Allied Insurance Company		38.27	31.38	48.31
	ICICI Lombard General Insurance Company Ltd		48.91	35.66	30.69
	The New India Assurance Company Ltd		28.62	25.12	13.75
	<b>Industry Avg</b>		<b>38.60</b>	30.72	30.92
<b>RoNW</b>	<b>Company</b>				
	<i>Consolidated</i>		5.68%	3.62%	9.38%
	<b>Peer Group:</b>				
	Star Health and Allied Insurance Company		14.35%	9.20%	7.38%
	ICICI Lombard General Insurance Company Ltd		17.17%	16.74%	17.25%
	The New India Assurance Company Ltd		5.13%	4.42%	3.51%
	<b>Industry Avg</b>		<b>12.22%</b>	10.12%	9.38%
<b>NAV per share</b>	<b>Company</b>				
	<i>Consolidated</i>		12.06	32.28	20.57
	<b>Peer Group:</b>				
	Star Health and Allied Insurance Company		108.35	119.47	128.39
	ICICI Lombard General Insurance Company Ltd		242.75	302.27	323.19
	The New India Assurance Company Ltd		132.55	136.02	233.88
	<b>Industry Avg</b>		<b>161.22</b>	185.92	228.49

Notes

\* Sourced from Prospectus dated November 12, 2024.

\*\*Not available as the relevant fiscal years have not been completed / information not disclosed

**14 Any other material information**

Particulars	Date	Remarks
Not Applicable		

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com